Synthesis of nanodiamond-daunorubicin conjugates to overcome multidrug chemoresistance in leukemia

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 2, 2014, Pages 359-369

  Man, Han B ^a   Kim, Hansung ^a   Kim, Ho Joong ^b   Robinson, Erik ^a   Liu, Wing Kam ^a   Chow, Edward Kai Hua ^c,d   Ho, Dean ^b  

^a Northwestern University   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chemoresistance; Drug delivery; Leukemia; Nanodiamond; Nanomedicine

Indexed keywords

CHEMORESISTANCE; DRUG DELIVERY; LEUKEMIA; NANODIAMOND; NANOMEDICINE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA; MOLECULAR DYNAMICS SIMULATION; NANODIAMONDS; NANOMEDICINE; TIME FACTORS;

EID: 84895069445     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.07.014     Document Type: Article

References (51)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011. CA: A Cancer Journal for Clinicians 2011, 61:212-236.
2. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
3. Ross D.D. Novel mechanisms of drug resistance in leukemia. Leukemia 2000, 14:467-473.
4. Nachman J.B., La M.K., Hunger S.P., Heerema N.A., Gaynon P.S., Hastings C., et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol 2009, 27:5189-5194.
5. Dulucq S., Bouchet S., Turcq B., Lippert E., Etienne G., Reiffers J., et al. Multidrug resistance gene (mdr1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
6. Walter R.B., Gooley T.A., van der Velden V.H.J., Loken M.R., van Dongen J.J.M., Flowers D.A., et al. Cd33 expression and p-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007, 109:4168-4170.
7. van der Kolk D.M., de Vries E.G.E., Müller M., Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002, 43:685-701.
8. Tiribelli M., Geromin A., Michelutti A., Cavallin M., Pianta A., Fabbro D., et al. Concomitant abcg2 overexpression and flt3-itd mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Cancer 2011, 117:2156-2162.
9. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. Abc transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10:147-156.
10. Boumendjel A., Baubichon-Cortay H., Trompier D., Perrotton T., Di Pietro A. Anticancer multidrug resistance mediated by mrp1: recent advances in the discovery of reversal agents. Med Res Rev 2005, 25:453-472.
11. Coley H. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. In: Zhou J, editor. Multi-drug resistance in cancer: Humana Press; 2010. p. 341-58.
12. Vauthier C., Dubernet C., Chauvierre C., Brigger I., Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release 2003, 93:151-160.
13. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
14. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
15. Man HB, Ho D. Diamond as a nanomedical agent for versatile applications in drug delivery, imaging, and sensing. physica status solidi (a). 2012;209:1609-18.
16. Ho D. Beyond the sparkle: the impact of nanodiamonds as biolabeling and therapeutic agents. ACS Nano 2009, 3:3825-3829.
17. Liang Y., Ozawa M., Krueger A. A general procedure to functionalize agglomerating nanoparticles demonstrated on nanodiamond. ACS Nano 2009, 3:2288-2296.
18. Petráková V., Taylor A., Kratochvílová I., Fendrych F., Vacík J., Kučka J., et al. Luminescence of nanodiamond driven by atomic functionalization: towards novel detection principles. Adv Funct Mater 2012, 22:812-819.
19. Schrand A.M., Huang H.J., Carlson C., Schlager J.J., Osawa E., Hussain S.M., et al. Are diamond nanoparticles cytotoxic?. J Phys Chem B 2007, 111:2-7.
20. Zhang X., Hu W., Li J., Tao L., Wei Y. A comparative study of cellular uptake and cytotoxicity of multi-walled carbon nanotubes, graphene oxide, and nanodiamond. Toxicol Res 2012, 1:62-68.
21. Huang H., Pierstorff E., Osawa E., Ho D. Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett 2007, 7:3305-3314.
22. Chen M., Pierstorff E.D., Lam R., Li S.-Y., Huang H., Osawa E., et al. Nanodiamond-mediated delivery of water-insoluble therapeutics. ACS Nano 2009, 3:2016-2022.
23. Zhang X.Q., Chen M., Lam R., Xu X.Y., Osawa E., Ho D. Polymer-functionalized nanodiamond platforms as vehicles for gene delivery. ACS Nano 2009, 3:2609-2616.
24. Chen M., Zhang X.-Q., Man H.B., Lam R., Chow E.K., Ho D. Nanodiamond vectors functionalized with polyethylenimine for sirna delivery. J Phys Chem Lett 2010, 1:3167-3171.
25. Alhaddad A., Adam M.-P., Botsoa J., Dantelle G., Perruchas S., Gacoin T., et al. Nanodiamond as a vector for sirna delivery to ewing sarcoma cells. Small 2011, 7:3087-3095.
26. Manus L.M., Mastarone D.J., Waters E.A., Zhang X.-Q., Schultz-Sikma E.A., MacRenaris K.W., et al. Gd(iii)-nanodiamond conjugates for mri contrast enhancement. Nano Lett 2009, 10:484-489.
27. Lam R., Chen M., Pierstorff E., Huang H., Osawa E.J., Ho D. Nanodiamond-embedded microfilm devices for localized chemotherapeutic elution. ACS Nano 2008, 2:2095-2102.
28. Man HB, Lam R, Chen M, Osawa E, Ho D. Nanodiamond-therapeutic complexes embedded within poly (ethylene glycol) diacrylate hydrogels mediate sequential drug elution. physica status solidi (a). 2012.
29. Chow EK, Zhang X-Q, Chen M, Lam R, Robinson E, Huang H, et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med. 2011;3:73ra21.
30. Kim H., Man H.B., Saha B., Kopacz A.M., Lee O.-S., Schatz G.C., et al. Multiscale simulation as a framework for the enhanced design of nanodiamond-polyethylenimine-based gene delivery. J Phys Chem Lett 2012, 3:3791-3797.
31. Lotfi K., Zackrisson A.-L., Peterson C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett 2002, 178:141-149.
32. Camarasa M.V., Castro-Galache M.D., Carrasco-García E., Garcia-Morales P., Saceda M., Ferragut J.A. Differentiation and drug resistance relationships in leukemia cells. J Cell Biochem 2005, 94:98-108.
33. Mohan N., Chen C.-S., Hsieh H.-H., Wu Y.-C., Chang H.-C. In vivo imaging and toxicity assessments of fluorescent nanodiamonds in caenorhabditis elegans. Nano Lett 2010, 10:3692-3699.
34. Yuan Y., Chen Y., Lui J.-H., Wang H., Liu Y. Biodistribution and fate of nanodiamonds in vivo. Diamond Relat Mater 2009, 18:95-100.
35. Schrand A.M., Huang H., Carlson C., Schlager J.J., Osawa E., Hussain S.M., et al. Are diamond nanoparticles cytotoxic?. J Phys Chem B 2006, 111:2-7.
36. Krueger A., Stegk J., Liang Y., Lu L., Jarre G. Biotinylated nanodiamond: simple and efficient functionalization of detonation diamond. Langmuir 2008, 24:4200-4204.
37. Ushizawa K., Sato Y., Mitsumori T., Machinami T., Ueda T., Ando T. Covalent immobilization of DNA on diamond and its verification by diffuse reflectance infrared spectroscopy. Chem Phys Lett 2002, 351:105-108.
38. Huang L.C.L., Chang H.-C. Adsorption and immobilization of cytochrome c on nanodiamonds. Langmuir 2004, 20:5879-5884.
39. Shimkunas R.A., Robinson E., Lam R., Lu S., Xu X., Zhang X.-Q., et al. Nanodiamond-insulin complexes as ph-dependent protein delivery vehicles. Biomaterials 2009, 30:5720-5728.
40. Berman E., Heller G., Santorsa J., McKenzie S., Gee T., Kempin S., et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991, 77:1666-1674.
41. Osawa E., Ho D., Huang H., Korobov M.V., Rozhkova N.N. Consequences of strong and diverse electrostatic potential fields on the surface of detonation nanodiamond particles. Diamond Relat Mater 2009, 18:904-909.
42. Schmidlin L., Pichot V., Comet M., Josset S., Rabu P., Spitzer D. Identification, quantification and modification of detonation nanodiamond functional groups. Diamond Relat Mater 2012, 22:113-117.
43. van der Kolk D.M., Vellenga E., Scheffer G.L., Müller M., Bates S.E., Scheper R.J., et al. Expression and activity of breast cancer resistance protein (bcrp) in de novo and relapsed acute myeloid leukemia. Blood 2002, 99:3763-3770.
44. Yanovich S., Hall R.E., Gewirtz D.A. Characterization of a k562 multidrug-resistant cell line. Cancer Res 1989, 49:4499-4503.
45. Panté N., Kann M. Nuclear pore complex is able to transport macromolecules with diameters of~39nm. Mol Biol Cell 2002, 13:425-434.
46. Gaumet M., Vargas A., Gurny R., Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008, 69:1-9.
47. Ohkuma S., Poole B. Fluorescence probe measurement of the intralysosomal ph in living cells and the perturbation of ph by various agents. Proc Natl Acad Sci 1978, 75:3327-3331.
48. Adnan A., Lam R., Chen H., Lee J., Schaffer D.J., Barnard A.S., et al. Atomistic simulation and measurement of ph dependent cancer therapeutic interactions with nanodiamond carrier. Mol Pharm 2010, 8:368-374.
49. Moore L., Chow EK-H, Osawa E., Bishop J.M., Ho D. Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression. Advanced Materials 2013, 25:3532-3541.
50. Singh A., Dilnawaz F., Mewar S., Sharma U., Jagannathan N.R., Sahoo S.K. Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and mri imaging for cancer therapy. ACS Appl Mater Interfaces 2011, 3:842-856.
51. Saad M., Garbuzenko O.B., Minko T. Co-delivery of sirna and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine 2008, 3:761-776.